Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

Lancet

Volumn 352, Issue 9127, 1998, Pages 515-521

  Rodenhuis, Sjoerd ^a   Richel, Dick J ^a   Van Der Wall, Elsken ^a   Schornagel, Jan H ^a   Baars, Joke W ^a   Koning, Caro C E ^a   Peterse, Johannes L ^a   Borger, Jacques H ^a   Nooijen, Willem J ^a   Bakx, Roel ^a   Dalesio, Otilia ^a   Rutgers, Emiel ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN; THIOTEPA;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VOMITING;

EID: 7344254625     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)01350-6     Document Type: Article

References (35)

1. 1 Antman Kh, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-79.
2. 2 Smigel K. Women flock to ABMT for breast cancer without final proof: phase III ABMT studies under way. J Natl Cancer Inst 1995; 87: 952-55.
3. 3 Gradishar WJ, Tallman MS, Abrams JS. High-dose chemotherapy for breast cancer. Ann Intern Med 1996; 125: 599-604.
4. 4 Frei III E, Antman K, Teicher B, Eder P, Schnipper L. Bone marrow autotransplantation for solid tumours - prospects. J Clin Oncol 1989; 7: 515-26.
5. 5 Frei III E, Teicher BA, Holden SA, Cathart KNS, Wang Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48: 6417-23.
6. 6 Peters WP, Ross M, Vredenburg JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk breast cancer. J Clin Oncol 1993; 11: 1132-43.
7. 7 Hurd DD, Peters WP. Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CLGB Protocol 9082). Cancer and Leukemia Group B. J Natl Cancer Inst Monogr 1995; 19: 41-44.
8. 8 De Vries EGE, Ten Vergert EM, Mastenbroek CG, Dalesio O, Rodenhuis S. Breast cancer studies in the Netherlands. Lancet 1996; 348: 407-08.
9. 9 Van Dongen JA. Subclavicular biopsy as a guideline for the treatment of breast carcinoma. World J Surg 1977; 1: 306-08.
10. 10 Van Tienhoven G, Borger JH, Passchier DH, et al. The prognostic significance of the axillary apex biopsy in clinically operable breast cancer. Eur J Cancer 1995; 31A: 1965-68.
11. 11 Danforth DN Jr, Findlay PA, McDonald HD, et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol 1986; 4: 655-62.
12. 12 Du Toit RS, Locker AP, Ellis IO, Elston CW, Blarney RW. Evaluation of the prognostic value of triple node biopsy in early breast cancer. Br J Surg 1990; 77: 163-67.
13. 13 Haagensen CD. Diseases of the breast, 2nd edn. Philadelphia: Saunders, 1976.
14. 14 Van der Wall E, Rutgers EJT, Holtkamp MJ, et al. Efficacy of up-front FEC-chemotherapy with an increased dose of epirubicin in high risk breast cancer. Br J Cancer 1996; 73: 1080-85.
15. 15 Van der Wall E, Schaake-Koning CCE, Van Zandwijk N, et al. The toxicity of radiotherapy following high-dose chemotherapy with peripheral stem cell support in high-risk breast cancer: a preliminary analysis. Eur J Cancer 1996; 32A: 1490-97.
16. 16 Van der Wall E, Richel DJ, Holtkamp MJ, et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral stem cell transplantation: correlation with graft size. Ann Oncol 1994; 5: 795-802.
17. 17 Van der Wall E, Nooijen WJ, Baars JW, et al. HIgh-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995; 71: 857-62.
18. 18 Rodenhuis S, Baars J, Schornagel JH, et al. Feasibility and toxicity study of a high-dose chemotherapy regimen incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 1992; 3: 855-60.
19. 19 De Graaf H, Willemse PHB, De Vries EGE, et al. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 1994; 30A: 150-53.
20. 20 Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more axillary nodes involved - five year results. J Clin Oncol 1997; 15: 2312-21.
21. 21 Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-45.
22. 22 Haioun C, Lepage E, Giselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131-37.
23. 23 Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-99.
24. 24 Eder JP, Elias A, Shea TC, et al. A phase I-II study of cyclophosphamide, thiotepa and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239-45.
25. 25 Peters WP, Eder JP, Henner WD, et al. High-dose combination alkylating agents with autologous bone marrow support: a phase I trial. J Clin Oncol 1986; 4: 646-54.
26. 26 Martin M, Diaz-Rubio E, Casado A, et al. Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 1992; 10: 433-37.
27. 27 O'Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993; 11: 2112-17.
28. 28 Van der Wall E, Beijnen JH, Rodenhuis S. High-dose chemotherapy regimens for solid tumors: a review. Cancer Treat Rev 1995; 21: 105-32.
29. 29 Schaake-Koning C, Hamersma-van der Linden E, Hart G, Engelsman E. Adjuvant chemo-and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys 1985; 11: 1759-63.
30. 30 Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996; 14: 66-69.
31. 31 Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171-77.
32. 32 García-Carbonero R, Hidalgo M, Paz-Ares L, et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 1997; 15: 3178-84.
33. 33 Bartelink H, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J Clin Oncol 1997; 15: 207-15.
34. 34 Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71-85.
35. 35 Van Dam FSAM, Schagen SB, Muller M, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-18.